RU-1205
 | |
| Identifiers | |
|---|---|
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H21FN4O |
| Molar mass | 364.424 g·mol−1 |
| 3D model (JSmol) | |
| |
RU-1205 is a kappa opioid receptor agonist used for pain treatment. It has high bioavailability (44.17 and 56.03% upon peroral and subcutaneous introduction).[1]
Granulated RU-1205 produced maximum analgesic effect within 4-h investigation and retained higher analgesic activity compared to that of parent substance.[2]
RU-1205 does not cause side effects typical of morphine and butorphanol including the development of withdrawal syndrome upon naloxone provocation and tolerance to analgesic activity upon 14-day administration.[3]
See also
[edit]References
[edit]- ^ Spasov AA, Smirnova LA, Rashchenko AI, Kuznetsov KA, Anisimova VA. [The absolute bioavailability of benzimidazole derivative RU-1205 in rats]. Eksp Klin Farmakol. 2014;77(1):17-9. Russian. PMID: 24649597.
- ^ Spasov AA, Smirnova LA, Grechko OIu, Rashchenko AI, Shtareva DM, Anisimova VA. [Pharmacokinetic and analgesic properties of tabletized dosage form of RU-1205-new imidazobenzimidazole derivative with kappa agonist activity]. Eksp Klin Farmakol. 2014;77(7):27-30. Russian. PMID: 25322651.
- ^ Grechko OY, Shtareva DM, Spasov AA, Litvinov LA, Rashchenko AI. STUDYING THE PHYSICAL DEPENDENCE ON AND TOLERANCE TO THE ANTINOCICEPTIVE EFFECT OF RU-1205 SUBSTANCE. Eksp Klin Farmakol. 2016 Aug;79(4):8-11. English, Russian. PMID: 29949697.
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |